Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Go back to Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease| (NASDAQ: MNPR) | Delayed: 117.56 -0.99 (0.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.55 | 52 Week High | $ | |||
| Open | $117.85 | 52 Week Low | $ | |||
| Day High | $119.00 | P/E | N/A | |||
| Day Low | $116.21 | EPS | $ | |||
| Volume | 82,204 | |||||
